EMA Recommends Granting a Marketing Authorisation for Nirogacestat By Ogkologos - July 3, 2025 135 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adult patients with progressing desmoid tumours Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Sodium Thiosulfate Approved to Reduce Chemo-Related Hearing Loss in Children with... October 6, 2022 FDA Approves Capivasertib with Fulvestrant for Breast Cancer November 23, 2023 What to Know About Kidney Cancer Genetic Conditions and Genetic Counseling June 9, 2021 Combination of Enzalutamide Plus Abiraterone Acetate and Prednisone Offers No Clinical... April 6, 2023 Load more HOT NEWS My Path to Becoming a Radiation Therapist The R50 Research Specialist Award: Ensuring a Stable Cancer Research Workforce Breast Cancer Surgery Choice May Affect Young Survivors’ Quality of Life Trastuzumab Deruxtecan Shows Antitumour Activity and Durable Responses in Heavily Pretreated...
